115 related articles for article (PubMed ID: 32370101)
1. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
Lima NC; Atkinson E; Bunney TD; Katan M; Huang PH
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370101
[TBL] [Abstract][Full Text] [Related]
2. Targeting
Pal SK; Somford DM; Grivas P; Sridhar SS; Gupta S; Bellmunt J; Sonpavde G; Fleming MT; Lerner SP; Loriot Y; Hoffman-Censits J; Valderrama BP; Andresen C; Schnabel MJ; Cole S; Daneshmand S
Future Oncol; 2022 Jul; 18(21):2599-2614. PubMed ID: 35608106
[TBL] [Abstract][Full Text] [Related]
3. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer.
Garje R; An J; Obeidat M; Kumar K; Yasin HA; Zakharia Y
Oncologist; 2020 Nov; 25(11):e1711-e1719. PubMed ID: 32790011
[TBL] [Abstract][Full Text] [Related]
5. FGFR3-TACC3 cancer gene fusions cause mitotic defects by removal of endogenous TACC3 from the mitotic spindle.
Sarkar S; Ryan EL; Royle SJ
Open Biol; 2017 Aug; 7(8):. PubMed ID: 28855393
[TBL] [Abstract][Full Text] [Related]
6. Transforming fusions of FGFR and TACC genes in human glioblastoma.
Singh D; Chan JM; Zoppoli P; Niola F; Sullivan R; Castano A; Liu EM; Reichel J; Porrati P; Pellegatta S; Qiu K; Gao Z; Ceccarelli M; Riccardi R; Brat DJ; Guha A; Aldape K; Golfinos JG; Zagzag D; Mikkelsen T; Finocchiaro G; Lasorella A; Rabadan R; Iavarone A
Science; 2012 Sep; 337(6099):1231-5. PubMed ID: 22837387
[TBL] [Abstract][Full Text] [Related]
7. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
[TBL] [Abstract][Full Text] [Related]
8. Complexity of FGFR signalling in metastatic urothelial cancer.
Rodriguez-Vida A; Saggese M; Hughes S; Rudman S; Chowdhury S; Smith NR; Lawrence P; Rooney C; Dougherty B; Landers D; Kilgour E; Arkenau HT
J Hematol Oncol; 2015 Oct; 8():119. PubMed ID: 26497743
[TBL] [Abstract][Full Text] [Related]
9. Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
Hosni S; Kilian V; Klümper N; Gabbia D; Sieckmann K; Corvino D; Winkler A; Saponaro M; Wörsdörfer K; Schmidt D; Hahn O; Zanotto I; Bertlich M; Toma M; Bald T; Eckstein M; Hölzel M; Geyer M; Ritter M; Wachten D; De Martin S; Alajati A
Cancer Res; 2024 Mar; 84(5):725-740. PubMed ID: 38175774
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.
Krook MA; Reeser JW; Ernst G; Barker H; Wilberding M; Li G; Chen HZ; Roychowdhury S
Br J Cancer; 2021 Mar; 124(5):880-892. PubMed ID: 33268819
[TBL] [Abstract][Full Text] [Related]
11. Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model.
Bergman DR; Wang Y; Trujillo E; Fernald AA; Li L; Pearson AT; Sweis RF; Jackson TL
Front Immunol; 2024; 15():1358019. PubMed ID: 38515743
[TBL] [Abstract][Full Text] [Related]
12. FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions.
Katoh M; Loriot Y; Brandi G; Tavolari S; Wainberg ZA; Katoh M
Nat Rev Clin Oncol; 2024 Apr; 21(4):312-329. PubMed ID: 38424198
[TBL] [Abstract][Full Text] [Related]
13. Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma.
Wu Y; Jin W; Wang Q; Zhou J; Wang Y; Tan Y; Cui X; Tong F; Yang E; Wang J; Kang C
Mol Ther; 2021 Nov; 29(11):3305-3318. PubMed ID: 34274537
[TBL] [Abstract][Full Text] [Related]
14. Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma.
Matin SF; Adibi M; Shah AY; Alhalabi O; Corn P; Guo C; Amirtharaj R; Xiao L; Lange S; Duose DY; Wang S; Pal S; Campbell MT
J Urol; 2024 Apr; ():101097JU0000000000003928. PubMed ID: 38573872
[TBL] [Abstract][Full Text] [Related]
15. Low-Dose Infigratinib Increases Bone Growth And Corrects Growth Plate Abnormalities In An Achondroplasia Mouse Model.
Demuynck B; Flipo J; Kaci N; Dambkowski C; Paull M; Muslimova E; Shah BP; Legeai-Mallet L
J Bone Miner Res; 2024 Apr; ():. PubMed ID: 38590263
[TBL] [Abstract][Full Text] [Related]
16. Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma.
Huang Q; Mitsiades I; Dowst H; Zarrin-Khameh N; Noor AB; Castro P; Scheurer ME; Godoy G; Mims MP; Mitsiades N
NPJ Precis Oncol; 2023 Nov; 7(1):123. PubMed ID: 37980380
[TBL] [Abstract][Full Text] [Related]
17. RNAi technology targeting the
Parker Kerrigan BC; Ledbetter D; Kronowitz M; Phillips L; Gumin J; Hossain A; Yang J; Mendt M; Singh S; Cogdell D; Ene C; Shpall E; Lang FF
Neurooncol Adv; 2020; 2(1):vdaa132. PubMed ID: 33241214
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and antitumour activity of the FGFR inhibitor erdafitnib in three paediatric CNS tumour patients.
Stepien N; Mayr L; Schmook MT; Raimann A; Dorfer C; Peyrl A; Azizi AA; Schramm K; Haberler C; Gojo J
Pediatr Blood Cancer; 2024 Mar; 71(3):e30836. PubMed ID: 38177074
[TBL] [Abstract][Full Text] [Related]
19. Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial.
Pal SK; Grivas P; Gupta S; Dizman N; Zengin Z; Valderrama BP; Rodriguez-Vida A; Roghmann F; Sevillano Fernandez E; Matin SF; Loriot Y; Sridhar SS; Sonpavde G; Fleming MT; Lerner SP; Bellmunt J; Master V; Tripathi A; Davis K; van Veenhuyzen D; Weng R; Daneshmand S
Eur Urol; 2024 Apr; ():. PubMed ID: 38580518
[No Abstract] [Full Text] [Related]
20. Re: FGFR Inhibition Augments Anti-PD-1 Efficacy in Murine FGFR3-mutant Bladder Cancer by Abrogating Immunosuppression.
St-Laurent MP; Black PC
Eur Urol; 2024 Apr; ():. PubMed ID: 38614823
[No Abstract] [Full Text] [Related]
[Next] [New Search]
